Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 5, 2026, 2:19 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–16 of 16 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: lintuzumab Clear all
Terminated Phase 2 Interventional Results available

Azacitidine and Lintuzumab in Treating Patients With Previously Untreated Myelodysplastic Syndromes

NCT00997243
View directory record Official record
Conditions
Leukemia, Myelodysplastic Syndromes
Interventions
lintuzumab, 5-azacytidine
Biological · Drug
Lead sponsor
Alison Walker
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated May 9, 2017 · Synced Sep 5, 2026, 2:19 PM EDT
Not listed Phase 3 Interventional

Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With Refractory or Relapsed Acute Myelogenous Leukemia

NCT00006045
View directory record Official record
Conditions
Leukemia
Interventions
lintuzumab, cytarabine, etoposide, mitoxantrone hydrochloride
Biological · Drug
Lead sponsor
Facet Biotech
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
40
States / cities
Los Angeles, California • Orange, California • Sacramento, California + 29 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2013 · Synced Sep 5, 2026, 2:19 PM EDT
Completed Phase 1 Interventional

A Safety Study of Lintuzumab in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome

NCT00283114
View directory record Official record
Conditions
Acute Myeloid Leukemia, Myelodysplastic Syndrome, Myeloproliferative Disorders, Chronic Myelomonocytic Leukemia
Interventions
lintuzumab
Drug
Lead sponsor
Seagen Inc.
Industry
Eligibility
18 Years and older
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
9
States / cities
Denver, Colorado • Decatur, Illinois • Indianapolis, Indiana + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2014 · Synced Sep 5, 2026, 2:19 PM EDT
Completed Phase 1 Interventional

Monoclonal Antibody Therapy in Treating Patients With Myelodysplastic Syndrome or Relapsed or Refractory Acute Myeloid Leukemia or Chronic Myelogenous Leukemia

NCT00002890
View directory record Official record
Conditions
Leukemia, Myelodysplastic Syndromes
Interventions
lintuzumab
Biological
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
16 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2001
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 24, 2013 · Synced Sep 5, 2026, 2:19 PM EDT
Completed Phase 1Phase 2 Interventional

Lintuzumab-Ac225 in Older Acute Myeloid Leukemia (AML) Patients

NCT02575963
View directory record Official record
Conditions
AML
Interventions
Cytarabine (Phase 1 only), Lintuzumab-Ac225, Furosemide (Phase 1 only), Spironolactone
Drug · Biological
Lead sponsor
Actinium Pharmaceuticals
Industry
Eligibility
60 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
16
States / cities
Los Angeles, California • Lexington, Kentucky • Louisville, Kentucky + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2023 · Synced Sep 5, 2026, 2:19 PM EDT
Not listed Phase 2 Interventional

Monoclonal Antibody in Treating Patients With Acute Myelogenous Leukemia

NCT00006084
View directory record Official record
Conditions
Leukemia
Interventions
lintuzumab
Biological
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 18, 2013 · Synced Sep 5, 2026, 2:19 PM EDT
Completed Phase 2 Interventional

Monoclonal Antibody Therapy and Chemotherapy in Treating Patients With Acute Promyelocytic Leukemia in Remission

NCT00002609
View directory record Official record
Conditions
Leukemia
Interventions
lintuzumab, cytarabine, idarubicin
Biological · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
12 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 2003
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 23, 2013 · Synced Sep 5, 2026, 2:19 PM EDT
Completed Phase 1 Interventional

Lintuzumab-Ac225 in Combination with Cladribine + Cytarabine + Filgastrim + Mitoxantrone (CLAG-M) for Relapsed/Refractory Acute Myeloid Leukemia

NCT03441048
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Lintuzumab-Ac-225, Cladribine, Cytarabine, Mitoxantrone, G-CSF
Biological · Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Milwuakee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 7, 2024 · Synced Sep 5, 2026, 2:19 PM EDT
Completed Phase 2 Interventional

A Study of Lintuzumab (SGN-33) in Combination With Low Dose Cytarabine in Patients 60+ Years With AML

NCT00528333
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Lintuzumab (SGN-33), Low dose cytarabine, Placebo
Drug
Lead sponsor
Seagen Inc.
Industry
Eligibility
60 Years and older
Enrollment
211 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
20
States / cities
Mobile, Alabama • Beverly Hills, California • Glendale, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2015 · Synced Sep 5, 2026, 2:19 PM EDT
Completed Phase 1 Interventional

A Phase I Study of Lintuzumab Combined With Lenalidomide in Patients With Myelodysplastic Syndromes (MDS)

NCT00502112
View directory record Official record
Conditions
Myelodysplastic Syndrome (MDS)
Interventions
lintuzumab, lenalidomide
Drug
Lead sponsor
Seagen Inc.
Industry
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
8
States / cities
Birmingham, Alabama • Denver, Colorado • Washington D.C., District of Columbia + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 11, 2011 · Synced Sep 5, 2026, 2:19 PM EDT
Completed Phase 2 Interventional

Chemotherapy Plus Monoclonal Antibody in Treating Patients With Acute Promyelocytic Leukemia

NCT00016159
View directory record Official record
Conditions
Leukemia
Interventions
filgrastim, lintuzumab, arsenic trioxide, idarubicin, tretinoin
Biological · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Not listed
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 15, 2013 · Synced Sep 5, 2026, 2:19 PM EDT
Completed Phase 2 Interventional

Chemotherapy in Treating Patients With Newly Diagnosed Acute or Chronic Myelogenous Leukemia or Myelodysplastic Syndrome

NCT00002800
View directory record Official record
Conditions
Leukemia, Myelodysplastic Syndromes, Neutropenia
Interventions
filgrastim, lintuzumab, cytarabine, etoposide, idarubicin
Biological · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2003
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 2, 2013 · Synced Sep 5, 2026, 2:19 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Phase I Study of Lintuzumab-Ac225 in Patients With Refractory Multiple Myeloma

NCT02998047
View directory record Official record
Conditions
Refractory Multiple Myeloma
Interventions
Lintuzumab AC 225
Drug
Lead sponsor
Actinium Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
5
States / cities
Los Angeles, California • Kansas City, Kansas • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2022 · Synced Sep 5, 2026, 2:19 PM EDT
Suspended Phase 1 Interventional

Testing an Anti-cancer Radio-Active Immunotherapy Called Lintuzumab Ac225 in Patients With High-Risk Myelodysplastic Syndrome That Has Not Responded to Other Treatment

NCT06888323
View directory record Official record
Conditions
Refractory Myelodysplastic Syndrome
Interventions
Actinium Ac 225 Lintuzumab, Bone Marrow Aspiration, Buccal Swab, Computed Tomography, Single Photon Emission Computed Tomography
Radiation · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Sep 5, 2026, 2:19 PM EDT
Suspended Phase 1 Interventional

Testing the Combination of Targeted Radiotherapy With Anti-Cancer Drugs, Venetoclax and ASTX-727, to Improve Outcomes for Adults With Newly Diagnosed Acute Myeloid Leukemia

NCT06802523
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Actinium Ac 225 Lintuzumab, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Decitabine and Cedazuridine, Venetoclax
Radiation · Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 23, 2026 · Synced Sep 5, 2026, 2:19 PM EDT
Not listed Phase 1Phase 2 Interventional

Venetoclax and Lintuzumab-Ac225 in AML Patients

NCT03867682
View directory record Official record
Conditions
Acute Myeloid Leukemia, Relapsed Adult AML
Interventions
Lintuzumab-Ac225, Venetoclax, Spironolactone
Biological · Drug
Lead sponsor
Actinium Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
5
States / cities
Los Angeles, California • Louisville, Kentucky • New Orleans, Louisiana + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2023 · Synced Sep 5, 2026, 2:19 PM EDT